Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Haffner

Showing results (151-160 of 169) with videos related to

Pageof 17
Sort By:
Cell Reports|October 10, 2023
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancerPreston D Crowell, Jenna M Giafaglione, Anthony E Jones, et al.
Oncotarget|July 10, 2018
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancerKarim Boudadi, Daniel L Suzman, Valsamo Anagnostou, et al.
Research Square|January 10, 2024
ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATESAzra Ajkunic, Erolcan Sayar, Martine P Roudier, et al.
Molecular Cancer Research : MCR|May 26, 2026
Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate CancerErolcan Sayar, Helen M Richards, Roman Gulati, et al.
NPJ Precision Oncology|May 17, 2024
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlatesAzra Ajkunic, Erolcan Sayar, Martine P Roudier, et al.
Molecular Cancer Research : MCR|January 27, 2026
OGDHL promotes prostate cancer progression and regulates neuroendocrine marker expression and nucleotide abundanceMatthew J Bernard, Andrea Gallardo, Angel Ruiz, et al.
The Journal of Pathology|October 18, 2023
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancerRadhika A Patel, Erolcan Sayar, Ilsa Coleman, et al.
JCO Precision Oncology|October 5, 2020
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate CancerDavid R Wise, Jeffrey A Schneider, Joshua Armenia, et al.
Cancer Research Communications|August 6, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted TherapiesHyun Jung Lee, Roman Gulati, Erolcan Sayar, et al.
Signal Transduction and Targeted Therapy|July 25, 2024
CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradationAlvaro Quintanal-Villalonga, Kenta Kawasaki, Esther Redin, et al.
Pageof 17

Showing results (151-160 of 169) with videos related to

Sort By:
Pageof 17
Cell Reports|October 10, 2023
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancerPreston D Crowell, Jenna M Giafaglione, Anthony E Jones, et al.
Oncotarget|July 10, 2018
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancerKarim Boudadi, Daniel L Suzman, Valsamo Anagnostou, et al.
Research Square|January 10, 2024
ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATESAzra Ajkunic, Erolcan Sayar, Martine P Roudier, et al.
Molecular Cancer Research : MCR|May 26, 2026
Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate CancerErolcan Sayar, Helen M Richards, Roman Gulati, et al.
NPJ Precision Oncology|May 17, 2024
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlatesAzra Ajkunic, Erolcan Sayar, Martine P Roudier, et al.
Molecular Cancer Research : MCR|January 27, 2026
OGDHL promotes prostate cancer progression and regulates neuroendocrine marker expression and nucleotide abundanceMatthew J Bernard, Andrea Gallardo, Angel Ruiz, et al.
The Journal of Pathology|October 18, 2023
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancerRadhika A Patel, Erolcan Sayar, Ilsa Coleman, et al.
JCO Precision Oncology|October 5, 2020
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate CancerDavid R Wise, Jeffrey A Schneider, Joshua Armenia, et al.
Cancer Research Communications|August 6, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted TherapiesHyun Jung Lee, Roman Gulati, Erolcan Sayar, et al.
Signal Transduction and Targeted Therapy|July 25, 2024
CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradationAlvaro Quintanal-Villalonga, Kenta Kawasaki, Esther Redin, et al.
Pageof 17